Ann Marie Chavez
Medical · Scottsdale, AZNPI 1992945299
Payments from drug & device makers
Across 1,058 payments — averaging $21.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- AstraZeneca$2K
- Novo Nordisk$2K
- Bayer$2K
- Amgen$1K
- Esperion Therapeutics, Inc.$1K
- plus $10K from 54 others
What the payments were for
- Consulting fees$1,6707%
- Speaking & faculty fees$9104%
- Food & beverage$20,24788%
- Education$1050%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,932 in reported general payments places this provider in the 95th percentile of 748 medical providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 156 | $242,932 |
| MounjaroTirzepatide | 137 | $143,422 |
| FarxigaDapagliflozin Propanediol | 69 | $58,144 |
| Xigduo XrDapaglifloz Propaned/Metformin | 43 | $36,128 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 22 | $28,892 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 26 | $22,607 |
| WegovySemaglutide | 16 | $21,832 |
| JardianceEmpagliflozin | 22 | $20,382 |
| TrulicityDulaglutide | 21 | $20,208 |
| EliquisApixaban | 20 | $17,182 |
| VascepaIcosapent Ethyl | 20 | $15,116 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $13,562 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $13,431 |
| LinzessLinaclotide | 18 | $9,674 |
| MyrbetriqMirabegron | 12 | $5,420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $1,656 | $264,764172 claims |
| Lilly USA, LLCMounjaro, Trulicity | $841 | $163,631158 claims |
| AstraZenecaFarxiga | $2,490 | $58,14469 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance | $264 | $42,99048 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $130 | $28,89222 claims |
| PfizerEliquis | $779 | $17,18220 claims |
| GSKTrelegy Ellipta | $248 | $13,56221 claims |
| AbbVieLinzess, Synthroid | $4,308 | $10,93647 claims |
| Astellas Pharma US IncMyrbetriq | $212 | $5,42012 claims |
| MerckBelsomra | $116 | $5,02212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 748 medical providers in Arizona.
Other medical in Scottsdale
- Robert CasquejoScottsdale$474K
- Darren WestScottsdale$206K
- Jamie WystrachScottsdale$79K
- Kendall JensonScottsdale$39K
- Emma ReeveScottsdale$15K
- Fiona BluntScottsdale$12K
- Francine MartynScottsdale$10K
- Victoria CarpenterScottsdale$9K
- Andrew HicksPeoria$460K
- Linda MoorsTucson$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.